Floatz logo

Apitegromab

Spinal Muscular Atrophy, Type III

Scholar Rock, Inc.monoclonal_antibodyPhase 3Active
BB
67/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
56/ 100
Competitive Position
89/ 100

Competitive context

4 Active assets in the Spinal Muscular Atrophy, Type III cohort.

Same molecule, other indications

Apitegromab is also rated in:

neuromuscular diseaseActive
BB
Indicative · Phase 3
69 / 100
View asset →
spinal muscular atrophy, type IIActive
BB
Indicative · Phase 3
67 / 100
View asset →
spinal muscular atrophyActive
BB
Indicative · Phase 3
67 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →